Skip to main content
. 2019 Oct 15;11(Suppl 1):S93–S99. doi: 10.1016/j.jcot.2019.10.004

Table 1.

Patient demographic and clinical characteristics.

Not on Anticoagulants n = 189 Not Reversed n = 84 Reversed n = 186 p
Age Median (IQR) 82 (76, 88) 83.5 (75.5, 88) 83.5 (78, 88) 0.39
Sex % Female (n) 68% (128) 71% (60) 62% (116) 0.29
Pre-ambulatory Status
 Walks without an assistive device 68% (128) 62% (50) 55% (100) 0.01a
 Walks with an assistive device 27% (50) 38% (31) 41% (75)
 Cannot walk 5% (9) 0 3% (6)
Prior Hip Fracture 9% (16) 8% (7) 11% (21) 0.54
Pre-injury Medications
 Cholinesterase Inhibitors 12% (22) 12% (10) 10% (19) 0.88
 Analgesic 15% (28) 26% (22) 26% (48) 0.02b
 Narcotic 15% (29) 31% (26) 27% (51) 0.004c
 Anti-arrhythmia 1% (2) 29% (24) 30% (56) <0.001d
 Beta Blocker 15% (29) 35% (33) 28% (54) <0.001e
 Calcium Channel Blockers 22% (42) 24% (20) 24% (44) 0.93
 Vitamin D 21% (40) 17% (14) 26% (48) 0.22
 Iron 6% (11) 8% (7) 9% (16) 0.55
 Potassium 11% (20) 18% (15) 19% (36) 0.05
 Statin 32% (61) 36% (30) 50% (93) 0.001f
 Medication Count Median (IQR) 5 (2, 8) 6 (4, 9) 7 (5, 10) <0.001g
Comorbidities
 Diabetes Mellitus 18% (34) 14% (12) 25% (46) 0.09
 Hypertension 63% (119) 62% (52) 65% (120) 0.91
 Congestive Heart Failure 8% (16) 14% (12) 23% (42) <0.001h
 Dementia 24% (46) 14% (12) 18% (34) 0.12
 COPD 15% (29) 10% (8) 15% (28) 0.40
 Smoker 8% (16) 6% (5) 6% (11) 0.58
 Cerebrovascular Accident 5% (10) 8% (7) 11% (21) 0.11
 Anemia 0 1% (1) 1% (1) 0.18
 Cancer 1% (2) 0 2% (4) 0.50
Admission Vital Signs
 SBP Median (IQR) 144 (129, 166) 148.5 (129, 168.5) 144 (127, 161) 0.53
 DBP Median (IQR) 75 (67, 86) 81 (70, 94) 77 (67.5, 89) 0.41
 RR Median (IQR) 18 (16, 18.5) 16 (16, 18) 18 (16, 18) 0.58
 HR Median (IQR) 79 (70, 90) 76 (68, 87.5) 80 (70, 89.5) 0.33
 O2 Median (IQR) 95 (93, 98) 94.5 (92, 97) 96 (94, 97) 0.21

Bonferroni-adjusted p = 0.025, N/A = not applicable, no values collected for this patient group; therefore, p-value not calculated. a = A higher proportion of reversed patients walked with an assistive device than those not on anticoagulants, no significant difference between those not on anticoagulants and those reversed, p = 0.04, or those not reversed and reversed, p = 0.23. b = A higher proportion of patients on anticoagulants than those not on anticoagulants were taking pre-injury analgesics, no significant difference between those not reversed and reversed, p = 0.95. c = A higher proportion of patients on anticoagulants than patients not on anticoagulants were taking narcotics, no significant difference between those reversed and not reversed, p = 0.55. d = A higher proportion of patients on anticoagulants than patients not on anticoagulants were taking anti-arrhythmia medication, no significant difference between those not reversed and reversed, p = 0.80. e = A higher proportion of reversed patients were than those not on anticoagulants were taking pre-injury beta-blockers, no significant difference between those not on anticoagulants and those not reversed, p = 0.36, or those reversed and not reversed, p = 0.08. f = A higher proportion of reversed patients were taking pre-injury statins than those not on anticoagulants, no significant difference between those not on anticoagulants and those not reversed, p = 0.58, or those reversed and not reversed, p = 0.03. g = Patients on anticoagulants had a higher medication count than those not on anticoagulants, no significant difference between those reversed and not reversed, p = 0.17. h = A higher proportion of reversed patients were than those not on anticoagulants had congestive heart failure, no significant difference between those not on anticoagulants and those not reversed, p = 0.14, or between those not reversed and reversed, p = 0.11.